{
    "organizations": [],
    "uuid": "684270f7a01a6543225f24711d5495ff006038c7",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/05/03/globe-newswire-iovance-biotherapeutics-to-host-first-quarter-2018-financial-results-conference-call-and-webcast-on-thursday-may-10-2018.html",
    "ord_in_thread": 0,
    "title": "Iovance Biotherapeutics to Host First Quarter 2018 Financial Results Conference Call and Webcast on Thursday, May 10, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "SAN CARLOS, Calif., May 03, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today announced that it will report its first quarter 2018 financial and operating results on Thursday, May 10, 2018. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.\nIn order to participate in the conference call, please dial 1-844-646-4465 (domestic) or 1-615-247-0257 (international) and reference the access code 2995797. The live webcast can be accessed under “News & Events” in the “Investors” section of the Company’s website at http://www.iovance.com/ or you may use the link: https://edge.media-server.com/m6/p/ouykqu6a .\nA replay of the call will be available from May 10, 2018 at 7:30 p.m. ET to May 17, 2018 at 8:30 p.m. ET. To access the replay, please dial 1-855-859-2056 (domestic) or 1-404-537-3406 (international) and reference the access code 2995797. The archived webcast will be available for thirty days in the Investors section of Iovance Biotherapeutics’ website at http://www.iovance.com/ .\nAbout Iovance Biotherapeutics, Inc.\nIovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer, and locally advanced or metastatic non-small cell lung cancer. For more information, please visit http://www.iovance.com .\nInvestor Contact:\nSarah McCabe\nStern Investor Relations, Inc.\n212-362-1200\nsarah@sternir.com\nMedia Contact:\nEvan Smith\nFTI Consulting\n212-850-5622\nevan.smith@fticonsulting.com\nSource:Iovance Biotherapeutics, Inc.",
    "published": "2018-05-03T16:01:00.000+03:00",
    "crawled": "2018-05-03T18:09:14.020+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "san",
        "carlos",
        "may",
        "globe",
        "newswire",
        "iovance",
        "biotherapeutics",
        "nasdaq",
        "iova",
        "biotechnology",
        "company",
        "developing",
        "novel",
        "cancer",
        "immunotherapy",
        "based",
        "lymphocyte",
        "til",
        "technology",
        "today",
        "announced",
        "report",
        "first",
        "quarter",
        "financial",
        "operating",
        "result",
        "thursday",
        "may",
        "management",
        "host",
        "conference",
        "call",
        "live",
        "audio",
        "webcast",
        "discus",
        "result",
        "provide",
        "corporate",
        "update",
        "et",
        "order",
        "participate",
        "conference",
        "call",
        "please",
        "dial",
        "domestic",
        "international",
        "reference",
        "access",
        "code",
        "live",
        "webcast",
        "accessed",
        "news",
        "event",
        "investor",
        "section",
        "company",
        "website",
        "http",
        "may",
        "use",
        "link",
        "http",
        "replay",
        "call",
        "available",
        "may",
        "et",
        "may",
        "et",
        "access",
        "replay",
        "please",
        "dial",
        "domestic",
        "international",
        "reference",
        "access",
        "code",
        "archived",
        "webcast",
        "available",
        "thirty",
        "day",
        "investor",
        "section",
        "iovance",
        "biotherapeutics",
        "website",
        "http",
        "iovance",
        "biotherapeutics",
        "iovance",
        "biotherapeutics",
        "biotechnology",
        "company",
        "focused",
        "development",
        "cancer",
        "immunotherapy",
        "product",
        "treatment",
        "various",
        "cancer",
        "company",
        "lead",
        "product",
        "candidate",
        "adoptive",
        "cell",
        "therapy",
        "using",
        "lymphocyte",
        "til",
        "technology",
        "investigated",
        "treatment",
        "patient",
        "metastatic",
        "melanoma",
        "recurrent",
        "metastatic",
        "squamous",
        "cell",
        "carcinoma",
        "head",
        "neck",
        "recurrent",
        "metastatic",
        "persistent",
        "cervical",
        "cancer",
        "locally",
        "advanced",
        "metastatic",
        "cell",
        "lung",
        "cancer",
        "information",
        "please",
        "visit",
        "http",
        "investor",
        "contact",
        "sarah",
        "mccabe",
        "stern",
        "investor",
        "relation",
        "sarah",
        "medium",
        "contact",
        "evan",
        "smith",
        "fti",
        "consulting",
        "source",
        "iovance",
        "biotherapeutics",
        "inc"
    ]
}